Bad news for Johnson & Johnson… The FDA – the Food & Drug Administration – said the laboratory’s vaccine could lead to an “increased risk” of developing rare neurological disease, Guillain-Barré syndrome. In all, in the 12.5 million vaccinees, 100 of them have developed GBS, including 95 severe cases requiring hospitalization. One case has died as well.
“While the chance of such cases is very low, it exceeds the rate of normally reported cases among the general population by a small degree”, the laboratory explained. By what is GBS? It is a peripheric nerve damage characterized by weak paralysis, or even progressive paralysis. It mostly starts from the legs and goes up, sometimes reaching lungs, heart, and nerves in the neck or brain, incurably leading to the sick’s death.
Yet, still according to the American regulator, symptoms of the disease break out in the 42 days following the injection of the vaccine. The FDA specified the administration “continues to find the known and potential benefits clearly outweigh the known and potential risks”, despite these observations. In the event of trouble to move, swallow, chew, or speak, double vision or inability to move one’s eye, people who have been given the vaccine must contact a doctor as soon as possible.
Note that, 3,000 to 6,000 develop GBS every year in the U.S.
